Vagus Nerve Stimulator Denied by Insurance? Epilepsy Criteria and How to Appeal

Vagus nerve stimulation (VNS) is an FDA-approved neurostimulation therapy involving a pulse generator implanted subcutaneously in the chest that delivers intermittent electrical stimulation to the left vagus nerve via a coiled lead. It is used primarily for drug-resistant epilepsy and, under a separate FDA indication, for treatment-resistant depression. Insurance denials for VNS remain common, often citing insufficient documentation of prior drug failures or misclassifying the device as experimental.

FDA Indications for VNS

Understanding the FDA clearance landscape is the starting point for any VNS appeal:

Epilepsy: VNS is FDA-approved as adjunctive therapy for reducing the frequency of seizures in patients aged 4 years and older with partial-onset seizures that are refractory to antiepileptic drugs (AEDs). The LivaNova VNS Therapy System received original FDA approval in 1997.

Treatment-Resistant Depression (TRD): VNS received FDA approval in 2005 as an adjunctive long-term treatment for chronic or recurrent depression in patients who have not had an adequate response to four or more adequate antidepressant treatments. Coverage for this indication varies widely among commercial insurers and is frequently denied.

Drug-Resistant Epilepsy: Documenting the AED Failure Requirement

The standard definition of drug-resistant epilepsy (also called refractory or pharmacoresistant epilepsy), established by the International League Against Epilepsy (ILAE), requires:

• Failure of two or more appropriately chosen and adequately dosed antiepileptic drug regimens (whether as monotherapy or in combination)
• Persistent seizure activity that significantly impacts quality of life

For insurance purposes, document each AED trial with:

• Drug name and specific dosing
• Duration of trial
• Blood level monitoring if applicable (confirming therapeutic dosing)
• Reason for discontinuation (inefficacy, intolerance, or adverse effect)
• Seizure frequency before and during the trial

Common AEDs that must be documented as tried and failed include levetiracetam, lamotrigine, valproate, carbamazepine, oxcarbazepine, lacosamide, and others appropriate to the patient's seizure type and epilepsy syndrome.

Eligibility for VNS vs. Surgical Resection

Insurers sometimes deny VNS in patients who have not undergone a formal epilepsy surgery evaluation. Many epilepsy centers require that patients be evaluated for surgical resectability before proceeding to VNS, since resection (e.g., temporal lobectomy for mesial temporal sclerosis) offers potential seizure freedom while VNS only reduces seizure frequency.

If your patient has had an epilepsy surgery evaluation and was found to be non-resection-eligible (no clear focal lesion, bilateral onset, eloquent cortex involvement, multifocal disease), document the evaluation and its findings explicitly. This demonstrates that VNS is being pursued after appropriate evaluation of all options.

VNS for Depression: The Uphill Coverage Battle

VNS for treatment-resistant depression (TRD) is among the most difficult insurance coverage battles. Despite FDA approval in 2005, CMS issued a non-coverage determination for Medicare VNS-TRD in 2007 that was only recently revisited. Most commercial insurers followed Medicare's lead and deny VNS-TRD routinely.

If you are pursuing VNS for TRD, your appeal should:

• Document failure of at least four adequate antidepressant treatments (the FDA label criterion), including medication name, duration, and dose
• Include documentation of prior ECT (electroconvulsive therapy) if applicable
• Cite the FDA approval and reference any updated CMS coverage developments
• Request External Independent Review: Complete Guide" class="auto-link">external review, as external reviewers are bound by FDA approval status and clinical evidence

Responsive Neurostimulation (RNS) as an Alternative

Responsive neurostimulation (RNS) is an FDA-approved closed-loop neurostimulation system (NeuroPace) that detects abnormal EEG activity and delivers stimulation in response. RNS is FDA-approved for refractory partial seizures with one or two foci.

Insurers occasionally suggest RNS as an alternative to VNS or deny one while approving the other. The choice between VNS and RNS requires careful clinical evaluation:

• RNS requires identifying specific seizure foci via SEEG or intracranial EEG
• VNS does not require a defined focus and is appropriate for multifocal or generalized epilepsy
• RNS involves intracranial implantation; VNS does not

Your epileptologist's specific recommendation for VNS vs. RNS should be documented and defended in the appeal.

Building the VNS Appeal

Step 1: Compile the complete AED treatment history with specific drug, dose, duration, and outcome for each agent.

Step 2: Include epilepsy monitoring unit (EMU) admission records documenting seizure characterization.

Step 3: Document epilepsy surgery evaluation and finding of non-resection eligibility, if applicable.

Step 4: Have your epileptologist write a detailed letter of medical necessity.

Step 5: For depression indication, document all four-plus antidepressant failures in detail.

Step 6: Request peer-to-peer review and escalate to external review if needed.

Fight Back With ClaimBack

VNS denials are reversible with the right documentation. ClaimBack helps patients with drug-resistant epilepsy and treatment-resistant depression build compelling appeals for life-improving neurostimulation therapy.

Start your appeal with ClaimBack

Related Reading

• What Is Medical Necessity?
• How to Write an Insurance Appeal Letter
• Common Reasons Insurance Claims Are Denied